BWBrainsWay Ltd. BWAY · NASDAQ
$11.98 -0.42% (-$0.05)
- Market cap
- $471.9M
- Enterprise value
- $416.6M
- P/E
- 49.4x
- Forward P/E
- 73.7x
- PEG
- 0.4x
- P/S
- 7.7x
- P/FCF
- 82.9x
- EV/EBITDA
- 34.2x
- ROIC
- 7.8%
- Gross margin
- 75.3%
- Net margin
- 15.7%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -4.5x
- Beta
- 0.15
- Free float
- 75.0%
About the company
BrainsWay Ltd. (BWAY) is a global company specializing in the development and production of non-invasive neurostimulation devices for the treatment of various neurological and psychiatric disorders. With innovative technologies and treatment approaches, including transcranial magnetic stimulation (TMS), BrainsWay Ltd. is a key player in the field of neuromodulation. The company focuses on providing effective and safe therapeutic options for patients with neurological and psychiatric disorders. BrainsWay Ltd. (BWAY) shares could be suitable for investors looking to invest in the innovative healthcare sector focused on neurological treatments.
Sector
Healthcare
Industry
Medical - Specialties
CEO
Hadar Levy
Employees
129
Headquarters
Jerusalem
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number